A. Miron

C. Crum, A. Miron, Emily E. K. Meserve, 2019, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression

F. McKeon, M. Nucci, M. Hirsch, 2010, Modern Pathology.

Identification of a Novel E2F3 Product Suggests a Mechanism for Determining Specificity of Repression by Rb Proteins

J. Nevins, R. Sears, S. Ishida, 2000, Molecular and Cellular Biology.

11q13 is a susceptibility locus for hormone receptor positive breast cancer

Patrick Neven, Michael Jones, Michael Bremer, 2012, Human mutation.

Title Interplay between BRCA 1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer

Loris, Fiona, Meindl, 2012 .

Testing for hereditary breast and ovarian cancer in the southeastern United States.

E. Winer, B. Rimer, J. Schildkraut, 2000, Annals of surgery.

Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.

A. Whittemore, J. Hopper, E. John, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer

S. Cross, M. Beckmann, P. Fasching, 2011, Cancer Epidemiology, Biomarkers & Prevention.

19p13.1 is a triple-negative-specific breast cancer susceptibility locus.

Daniel J. Park, Julian Peto, Kamila Czene, 2012, Cancer research.

SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis

W. Hahn, A. Richardson, L. Zou, 2009, Science Signaling.

A candidate precursor to serous carcinoma that originates in the distal fallopian tube

J. Garber, F. McKeon, D. Cramer, 2007 .

The role of genetic breast cancer susceptibility variants as prognostic factors.

Jaana M. Hartikainen, S. Cross, M. Beckmann, 2012, Human molecular genetics.

BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays

A. Whittemore, G. Giles, J. Hopper, 2007, The American journal of surgical pathology.

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

J. S. Hoffman, W. Chung, V. Pankratz, 2012, Human mutation.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Mads Thomassen, Stephen Fox, Dieter Niederacher, 2011, Breast Cancer Research.

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

S. Gautam, A. Richardson, D. Sgroi, 2010, Breast Cancer Research.

A recurrent mutation in PALB2 in Finnish cancer families

Katri Pylkäs, Arja Jukkola-Vuorinen, Mervi Grip, 2007, Nature.

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

G. Shapiro, E. Swisher, M. Capelletti, 2013, Proceedings of the National Academy of Sciences.

Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.

Xiaowei Chen, J. Weaver, A. Godwin, 2008, Human molecular genetics.

Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data

Xuegong Zhang, Qian Shi, Wing H Wong, 2006, BMC Bioinformatics.

BRCA1 Supports XIST RNA Concentration on the Inactive X Chromosome

C. Deng, R. Greenberg, D. Livingston, 2002, Cell.

Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.

Alice S Whittemore, Gail Gong, A. Whittemore, 2007, JAMA.

Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube

G. Ning, F. McKeon, B. Quade, 2010, The Journal of pathology.

Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

M. Muto, M. Hirsch, C. Crum, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evidence for a Latent Precursor (p53 Signature) that May Precede Serous Endometrial Intraepithelial Carcinoma

C. Crum, G. Mutter, A. Miron, 2008, Modern Pathology.

Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification

R. Drapkin, M. Nucci, C. Crum, 2008, International Journal of Gynecological Pathology.

Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship

R. Berkowitz, C. Feltmate, M. Muto, 2007, The American journal of surgical pathology.

Genomic regions associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study

R. Elston, D. Beer, A. Chak, 2017, PloS one.

BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research

A. Whittemore, W. Chung, D. Seminara, 2009, Breast Cancer Research and Treatment.

Circulating colony stimulating factor-1 and breast cancer risk.

Graham A Colditz, Rulla M Tamimi, Susan E Hankinson, 2008, Cancer research.

Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.

P. Miron, A. Miron, J. D. Iglehart, 2007, The Journal of surgical research.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.

S. Cross, M. Beckmann, P. Fasching, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome-wide association analysis identifies three new breast cancer susceptibility loci

Michael Jones, Nazneen Rahman, Daniel J. Park, 2012, Nature Genetics.

Cervical mesonephric hyperplasia lacks KRAS/NRAS mutations

M. Nucci, A. Miron, J. K. Schoolmeester, 2017, Histopathology.

Coexisting Intraepithelial Serous Carcinomas of the Endometrium and Fallopian Tube: Frequency and Potential Significance

M. Nucci, M. Hirsch, C. Crum, 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

A BAC Transgene Expressing Human CFTR under Control of Its Regulatory Elements Rescues Cftr Knockout Mice

Austin E. Gillen, M. Drumm, C. Hodges, 2019, Scientific Reports.

A candidate precursor to serous carcinoma that originates in the distal fallopian tube (J Pathol 2007; 211: 26–35)

J. Garber, M. Nucci, A. Miron, 2007, The Journal of pathology.

Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma

C. Crum, B. Kong, A. Miron, 2008, Clinical Cancer Research.

BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles

A. Richardson, A. Miron, E. Matros, 2005, Breast Cancer Research and Treatment.

Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers

A. Richardson, S. Schnitt, J. Garber, 2009, The American journal of surgical pathology.

Genomics NFk B Activation-Induced Anti-apoptosis Renders HER 2-Positive Cells Drug Resistant and Accelerates Tumor Growth

T. Bowman, P. Miron, S. Rodig, 2014 .

NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth

T. Bowman, P. Miron, S. Rodig, 2013, Molecular Cancer Research.

Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer.

A. Richardson, D. Livingston, S. Ganesan, 2005, Cold Spring Harbor symposia on quantitative biology.

Frequency of germline and somatic BRCA1 mutations in ovarian cancer.

Torn, Vickie, A. Berchuck, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Prevalence of Pathogenic BRCA 1 Mutation Carriers in 5 US Racial / Ethnic Groups

Dee W. West, Alice S. Whittemore, Gail Gong, 2007 .

Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high‐grade serous carcinomas

R. Berkowitz, C. Feltmate, M. Muto, 2018, The Journal of pathology.

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis

R. Drapkin, A. Ligon, M. Birrer, 2013, Oncogene.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Christiana Kartsonaki, Mads Thomassen, Etienne Rouleau, 2011, Human molecular genetics.

9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

S. Cross, R. Schulz-Wendtland, M. Beckmann, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.

Xiaowei Chen, J. Weaver, A. Godwin, 2008, Human molecular genetics.

Breast and Ovarian Cancer in Relatives of Cancer Patients, with and without BRCA Mutations

A. Whittemore, E. John, D. West, 2006, Cancer Epidemiology Biomarkers & Prevention.

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Mads Thomassen, Nina Ditsch, Dieter Niederacher, 2009, Human molecular genetics.

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

F. Couch, B. Karlan, J. Benítez, 2011, Journal of the National Cancer Institute.

Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years

A. Whittemore, N. Boyd, J. Hopper, 2008, Breast Cancer Research and Treatment.

Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab

J. Hopper, E. John, M. Southey, 2016, Genetics in Medicine.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS Genetics.

Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, PloS one.

Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

F. Couch, T. Rebbeck, J. Benítez, 2011, Human molecular genetics.

Experimental Evolution of Legionella pneumophila in Mouse Macrophages Leads to Strains with Altered Determinants of Environmental Survival

R. Isberg, A. Miron, A. Ensminger, 2012, PLoS pathogens.

The Crucial p53-Dependent Oncogenic Role of JAB1 in Osteosarcoma in vivo

Brendan H. Lee, Guang Zhou, Yuqing Chen, 2020, Oncogene.

Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer

Marc Vidal, Dieter Niederacher, Roderic Guigó, 2011, PLoS biology.

11q13 is a susceptibility locus for hormone receptor positive breast cancer

Jaana M. Hartikainen, S. Cross, R. Schulz-Wendtland, 2012, Human mutation.

Retrograde signaling by a mtDNA-encoded non-coding RNA preserves mitochondrial bioenergetics

K. Pandit, N. Kaminski, D. Townsend, 2020, Communications Biology.

PALB2 mutations in familial breast and pancreatic cancer

P. Miron, K. Nathanson, J. Garber, 2011, Familial Cancer.

A 27 kd protein of E. coli promotes antitermination of replication in vitro at a sequence-specific replication terminus

D. Bastia, A. Miron, S. Kaul, 1993, Cell.

ArWtmmidon of ReplkSiun In Vitro at a Seque~ic Rep Terminus

A. Miron, S. Kaul, S. Natarajan, 1993 .

The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

J. Struewing, J. Hopper, E. John, 2006, Cancer Epidemiology Biomarkers & Prevention.

A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies

M. Drumm, C. Hodges, C. Cotton, 2018, PloS one.

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia

J. Maciejewski, J. Pink, H. Carraway, 2019, Clinical Cancer Research.

Activation of distant replication origins in vivo by DNA looping as revealed by a novel mutant form of an initiator protein defective in cooperativity at a distance.

D. Bastia, A. Miron, S. Mukherjee, 1992, The EMBO journal.

Multiple pathways of copy control of gamma replicon of R6K: mechanisms both dependent on and independent of cooperativity of interaction of tau protein with DNA affect the copy number.

D. Bastia, A. Miron, I. Patel, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Replication of plasmid R6K origin gamma in vitro. Dependence on dual initiator proteins and inhibition by transcription.

D. Bastia, A. Miron, W. Kelley, 1991, The Journal of biological chemistry.

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)

G Rennert, N Weerasooriya, K Offit, 2009, British Journal of Cancer.

Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

W. Chung, R. Nussbaum, D. Steinemann, 2014, Cancer Epidemiology, Biomarkers & Prevention.

q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012 .

Validation study of the lambda model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women

G. Glendon, C. Apicella, H. Ozçelik, 2007, Clinical genetics.

Evaluation of significant genome-wide association studies risk — SNPs in young breast cancer patients

R. Tamimi, Qiyuan Li, P. Miron, 2019, PloS one.

Lethal neonatal case and review of primary short-chain enoyl-CoA hydratase (SCEH) deficiency associated with secondary lymphocyte pyruvate dehydrogenase complex (PDC) deficiency.

S. Ferdinandusse, R. Wanders, D. Kerr, 2017, Molecular genetics and metabolism.

An Amish founder variant consolidates disruption of CEP55 as a cause of hydranencephaly and renal dysplasia

S. Ellard, E. Baple, A. Crosby, 2019, European Journal of Human Genetics.

Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk

P. Fasching, J. Cerhan, D. Noh, 2011, British Journal of Cancer.

Association for Academic Surgery, 2006 Rapamycin Inhibits Proliferation of Estrogen-Receptor-Positive Breast Cancer Cells 1

P. Miron, A. Miron, J. D. Iglehart, 2007 .

Reply to Ashktorab et al.: Mutational landscape of colon cancers in African Americans

M. Adams, R. Elston, J. Lutterbaugh, 2015, Proceedings of the National Academy of Sciences.

Molecular and Cellular Pathobiology 19 p 13 . 1 Is a Triple-Negative – Speci fi c Breast Cancer Susceptibility Locus

Xiaoqing, Daniel J. Park, Arif, 2012 .

Diagnostic Chest X-Rays and Breast Cancer Risk before Age 50 Years for BRCA1 and BRCA2 Mutation Carriers

A. Whittemore, G. Giles, J. Hopper, 2013, Cancer Epidemiology, Biomarkers & Prevention.

Integrated Systems and Technologies Cancer Research Integrated Profiling Reveals a Global Correlation between Epigenetic and Genetic Alterations in Mesothelioma

R. M. Simpson, B. Christensen, C. Marsit, 2010 .

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Communications.

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

V. Pankratz, F. Couch, O. Olopade, 2010, Cancer research.

Common variants at 12 p 11 , 12 q 24 , 9 p 21 , 9 q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, David Evans, 2017 .

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, Dennis J. Hazelett, 2014, Nature Genetics.

Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.

Bernard T. Lee, S. Troyan, N. Tung, 2009, Cancer research.

The AIB 1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers

J. Struewing, J. Hopper, E. John, 2006 .

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

V. Pankratz, F. Couch, T. Rebbeck, 2011, Human molecular genetics.

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.

F. Couch, B. Bonanni, J. Benítez, 2009, Human molecular genetics.

9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

S. Cross, R. Schulz-Wendtland, M. Beckmann, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Coexisting Intraepithelial Serous Carcinomas of the Endometrium and Fallopian Tube: Frequency and Potential Significance

M. Nucci, M. Hirsch, C. Crum, 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

PIK3CA mutations in in situ and invasive breast carcinomas.

D. Carrasco, L. Macconaill, K. Polyak, 2010, Cancer research.

Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab

J. Hopper, E. John, M. Southey, 2016, Genetics in Medicine.

Performance of Prediction Models for BRCA Mutation Carriage in Three Racial/Ethnic Groups: Findings from the Northern California Breast Cancer Family Registry

A. Whittemore, E. John, D. West, 2009, Cancer Epidemiology Biomarkers & Prevention.